Literature DB >> 6267981

Polyneuropathy with monoclonal gammopathy: studies of 11 patients.

M C Dalakas, W K Engel.   

Abstract

Among patients with chronic idiopathic nonfamilial polyneuropathy studied 3 to 21 years after onset, we identified 11 cases associated with monoclonal gammopathy (MCG) (5 with IgGk, 4 with IgMk, 2 with IgG lambda). The patients, aged 29 to 80 years, presented with sensorimotor polyneuropathy of insidious onset and slow, nonfluctuating progression, delayed motor and sensory nerve conduction, and increased cerebrospinal fluid (CSF) protein. None of the patients in the initial or follow-up study (mean, 9.2 years) had or developed signs of multiple myeloma, malignant plasma cell dyscrasia, macroglobulinemia syndrome, amyloidosis, neoplasia, or other associated illness. The CSF revealed abnormalities of protein electrophoresis or immunoelectrophoresis in 9 of the 11 patients. Three of 5 sural nerve biopsies studied by immunofluorescence demonstrated deposition in nerve fibers of the light chain characteristic of the abnormal circulating immunoglobulin. The findings suggest that these patients form a distinct subset of the dysimmune neuropathies. Although the immunoglobulin deposition and abnormal protein patterns in serum and CSF could be secondary to nerve damage, we propose that an immunopathological mechanism underlies the neuropathy. Immunosuppressants had minimal to marked beneficial effect in 4 of 5 patients, indicating that this polyneuropathy is potentially treatable.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6267981     DOI: 10.1002/ana.410100109

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  24 in total

Review 1.  Treatment of chronic inflammatory demyelinating polyneuropathy.

Authors:  G Comi; L Roveri
Journal:  Ital J Neurol Sci       Date:  1998-10

2.  Amyloid-like IgM deposition neuropathy: a distinct clinico-pathologic and proteomic profiled disorder.

Authors:  Juan J Figueroa; E Peter Bosch; P James B Dyck; Wolfgang Singer; Julie A Vrana; Jason D Theis; Ahmet Dogan; Christopher J Klein
Journal:  J Peripher Nerv Syst       Date:  2012-06       Impact factor: 3.494

3.  Successful treatment of IgM paraproteinaemic neuropathy with fludarabine.

Authors:  H C Wilson; M P Lunn; S Schey; R A Hughes
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-05       Impact factor: 10.154

4.  Characterization of amyloid deposits in biopsies of 15 with "sporadic" (non-familial or plasma cell dyscrasia amyloid polyneuropathy.

Authors:  M C Dalakas; G Cunningham
Journal:  Acta Neuropathol       Date:  1986       Impact factor: 17.088

5.  The clinical spectrum of peripheral neuropathies associated with benign monoclonal IgM, IgG and IgA paraproteinaemia. Comparative clinical, immunological and nerve biopsy findings.

Authors:  K B Yeung; P K Thomas; R H King; H Waddy; R G Will; R A Hughes; N A Gregson; S Leibowitz
Journal:  J Neurol       Date:  1991-10       Impact factor: 4.849

6.  Proximal motor neuropathy, IgA paraproteinaemia and anti-myelin-associated glycoprotein reactivity.

Authors:  T Hemachudha; P Phanuphak; K Phanthumchinda; S Kasempimolporn
Journal:  Postgrad Med J       Date:  1989-09       Impact factor: 2.401

Review 7.  Plasmapheresis in paraproteinemia.

Authors:  H H Euler; N Schmitz; H Löffler
Journal:  Blut       Date:  1985-06

Review 8.  Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies.

Authors:  Michael Pt Lunn; Eduardo Nobile-Orazio
Journal:  Cochrane Database Syst Rev       Date:  2016-10-04

9.  The mouse blood-brain barrier and blood-nerve barrier for IgG: a tracer study by use of the avidin-biotin system.

Authors:  R J Seitz; K Heininger; G Schwendemann; K V Toyka; W Wechsler
Journal:  Acta Neuropathol       Date:  1985       Impact factor: 17.088

10.  Polyneuropathy with monoclonal gammopathy: glycolipids are frequently antigens for IgM paraproteins.

Authors:  A A Ilyas; R H Quarles; M C Dalakas; R O Brady
Journal:  Proc Natl Acad Sci U S A       Date:  1985-10       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.